Healthcare >> CEO Interviews >> February 23, 2026
Robert P. Eno joined HeartBeam Inc. as President in 2023 and became Chief Executive Officer in 2024. Before that, he was CEO of Preview Medical, a diagnostic equipment company creating a new category of real-time, in vivo tissue classification for solid tumor cancers using machine learning and proprietary optical signals. Earlier, he served as Senior Vice President of Marketing for HeartFlow leading marketing and product functions for a new category of personalized, noninvasive testing for heart disease, including its initial product, HeartFlow FFRCT. He has also held senior marketing and sales leadership roles at OptiMedica (acquired by Abbott), NeoGuide Systems (acquired by Intuitive) and Avantec Vascular (acquired by Goodman). Mr. Eno began his career at Guidant, where he held marketing and strategic planning roles in the vascular intervention business. He holds an MBA from the Stanford Graduate School of Business and a bachelor’s from Stanford University. Profile
Word count: 4,023
TWST: For readers who may just be hearing about HeartBeam, explain to us what clinical problem you are trying to solve and why hasn’t that been able to be solved with
